Portal Hypertension Completed Phase 1 / 2 Trials for Octreotide (DB00104)

Also known as: Hypertension Portal / Hypertension, Portal / Portal hypertensions

IndicationStatusPhase
DBCOND0029015 (Portal Hypertension)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01188733Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With CirrhosisPrevention